Stockscreener 앱 받기
1.03
3.00%
0.03
시간 외 거래:
1.01
-0.02
-1.94%
전일 마감가:
$1.00
열려 있는:
$1.005
하루 거래량:
15,875
Relative Volume:
0.22
시가총액:
$2.03M
수익:
-
순이익/손실:
$-22.56M
주가수익비율:
-0.5337
EPS:
-1.93
순현금흐름:
$-16.12M
1주 성능:
+5.10%
1개월 성능:
-11.21%
6개월 성능:
-47.45%
1년 성능:
+211.18%
1일 변동 폭
$1.00
$1.05
1주일 범위:
$0.99
$1.13
52주 변동 폭
$0.231
$4.3785
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
명칭
Cyclacel Pharmaceuticals Inc
전화
908-517-7330
주소
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2020-04-27 | 재개 | ROTH Capital | Buy |
| 2018-09-07 | 개시 | Ladenburg Thalmann | Buy |
| 2015-10-16 | 개시 | H.C. Wainwright | Buy |
| 2010-02-04 | 개시 | Roth Capital | Buy |
| 2009-10-28 | 개시 | Merriman | Buy |
| 2008-08-12 | 개시 | Piper Jaffray | Buy |
| 2008-03-12 | 재확인 | Cantor Fitzgerald | Buy |
| 2008-03-12 | 재확인 | Collins Stewart | Buy |
| 2008-03-12 | 재확인 | Needham & Co | Buy |
| 2007-11-27 | 재확인 | Cantor Fitzgerald | Buy |
| 2007-08-10 | 재확인 | Cantor Fitzgerald | Buy |
| 2007-06-04 | 재확인 | Needham & Co | Buy |
| 2007-04-23 | 개시 | Lazard Capital | Buy |
| 2007-04-10 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Cyclacel Pharmaceuticals Inc 주식(CYCC)의 최신 뉴스
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - StockTitan
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com UK
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - StockTitan
Cyclacel Pharmaceuticals Inc (CYCC)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Metric Analysis: Cyclacel Pharmaceuticals Inc (CYCC)’s Key Ratios in the Limelight - The Dwinnex
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Nasdaq
You might want to take a look at Cyclacel Pharmaceuticals Inc (CYCC) now - SETE News
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Cyclacel Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com UK
Geopark Ltd, Cyclacel Pharmaceuticals, Another 3 Companies Have A High Estimated Dividend Yield - Via News Agency
Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com Canada
Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com UK
Cyclacel Pharmaceuticals faces Nasdaq delisting - Investing.com
Cyclacel Pharmaceuticals faces Nasdaq delisting By Investing.com - Investing.com UK
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript - MSN
Cyclacel Pharmaceuticals changes its auditor - Investing.com
Cyclacel Pharmaceuticals changes its auditor By Investing.com - Investing.com UK
Cyclacel stock hits 52-week low at $1.21 amid market challenges - Investing.com
Cyclacel stock hits 52-week low at $1.21 amid market challenges - Investing.com UK
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
CYCC’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ratio Revelations: Cyclacel Pharmaceuticals Inc (CYCC)’s Financial Metrics in the Spotlight - The Dwinnex
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Cyclacel reports progress in fadraciclib study - Investing.com
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates - MSN
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - StockTitan
San Juan Basin Royalty Trust, Cyclacel Pharmaceuticals, Another 4 Companies Have A High Estimated Dividend Yield - Via News Agency
Cyclacel Pharmaceuticals (CYCC) to Release Quarterly Earnings on Wednesday - Defense World
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results - StockTitan
Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results - Morningstar
Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) Path To Profitability - Simply Wall St
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Shares Sold by Acadian Asset Management LLC - Defense World
Cyclacel Pharmaceuticals (CYCC) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance
Cyclacel Pharmaceuticals Inc (CYCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cyclacel Pharmaceuticals Inc 주식 (CYCC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rombotis Spiro George | President and CEO |
Dec 21 '23 |
Buy |
3.31 |
6,070 |
20,122 |
68,658 |
0.87%
자본화:
|
볼륨(24시간):